Peter A. Ljubenkov

MD

Neurologist
Natural science enthusiast, amateur artist and proud dad

Dr. Peter A. Ljubenkov is a behavioral neurologist who specializes in caring for patients experiencing memory, language and behavioral changes due to neurological conditions, such as Alzheimer's disease, Lewy body dementia and other causes of dementia. He has special expertise in diagnosing and treating frontotemporal dementia (a group of neurodegenerative diseases that affect the frontal and temporal lobes) and related conditions, including progressive supranuclear palsy and corticobasal degeneration. Ljubenkov also serves as the associate fellowship director of the UCSF Memory and Aging Center's Behavioral Neurology Training Program fellowship, which trains doctors for careers in research and clinical care involving patients with dementia.

In research, Ljubenkov is active in clinical therapeutic trials, studies enrolling human participants to explore new potential treatments for patients with dementia.

Ljubenkov earned his medical degree at Lewis Katz School of Medicine at Temple University. He completed a residency in neurology at the University of California, San Diego, followed by a fellowship in behavioral neurology at UCSF.

  • Education

    Lewis Katz School of Medicine, MD, 2011

  • Residencies

    UC San Diego, Neurology, 2015

  • Fellowships

    UCSF, Behavioral Neurology, 2018

  • Academic Title

    Assistant Professor

We are entering a renaissance of discoveries in the treatment of dementia. It is my passion to aid the search for a cure.

Clinics I work with

Memory and Aging Center

Joan and Sanford I. Weill Neurosciences Building

1651 Fourth St., Suite 212
San Francisco, CA 94158

My reviews

4.9

Overall Experience
35 Reviews
Explained things in a way that was easy to understand
34 Reviews
Did the doctor pay attention to your concerns
34 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
33 Reviews
Knew the important information about your medical history
35 Reviews
The provider showed respect for what you had to say
34 Reviews
The provider spent enough time with me
35 Reviews
Decorative Caduceus

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior & Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by ...

Recruiting

Decorative Caduceus

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) P...

Incidence of adverse events

Recruiting

Decorative Caduceus

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

The ADAS-Cog is an in-person examiner-administered, structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing ...

Recruiting

Decorative Caduceus

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Incidence of adverse events [AEs] and serious adverse events [SAEs] as assessed by clinically significant abnormal physical examination findings; changes in vital signs; 12-lead electrocardiogram [ECG]; magnetic resonance imaging ...

Recruiting

Share